We retrospectively evaluated the effectiveness of budesonide orodispersible tablets (BOT) in children with eosinophilic esophagitis (EoE) followed up at our center. A total of 17 children were treated with BOT 0.5 mg twice daily after a median time from diagnosis of 16 months (interquartile range IQR: 11-28.5). Previous treatments included proton-pump inhibitors, food elimination diets, and topical swallowed corticosteroids (TSC). After 3 months, 11/17 (65%) patients were in clinical remission. 8/17 (47%) patients repeated an endoscopy after a median time of 11.5 months (6.75-16.75 IQR); 6/8 (75%) were in endoscopic remission and 7/8 (87.5%) achieved histological remission. Eosinophils count at histology significantly decreased from baseline (30 15-50 IQR to 6 6-9 IQR, p = 0.03]. 3/4 (75%) patients who previously failed TSC achieved complete remission on BOT. After a median follow-up of 12.5 months (6.25-21 IQR), 11/17 (65%) patients were still on BOT treatment, and 9/11 (82%) were in clinical remission. No adverse events were reported.
Pochesci et al. (Tue,) studied this question.